digital health tools glp-1 weight management Impact of Engagement on Loss Outcomes in Obesity Among Individuals Using and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study Noom GLP-1 Support Maintains Weight

Shamji MF, De Vos C, Sharan A

Interestingly, the SURPASS-2 trial found that patients on tirzepatide 5 mg experienced less nausea (17.4%) and vomiting (5.7%) compared to those on semaglutide 1 mg, who reported 19.2% nausea and 8.1% vomiting, despite tirzepatide leading to greater weight loss

Smoothies that stall progress are typically high in sugar (from excessive fruit or juice) and low in protein

Dermal lipogenesis inhibits adiponectin production in human dermal fibroblasts while exogenous adiponectin administration prevents against UVA-induced dermal matrix degradation in human skin

Its weight-management evidence comes largely from the SURMOUNT trial program published in The New England Journal of Medicine in 2022, with SURMOUNT-OSA extending the data to obstructive sleep apnea in 2024

A specialty drug management program is a structured clinical and operational framework that a PBM uses to oversee high-cost, complex medications